Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
BASEL, Switzerland and CAMBRIDGE, Mass., April 27, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel in Boston, MA.
Event: 42nd Annual Deutsche Bank Health Care Conference
Date: Wednesday, May 3rd
Time: 4:10 PM EDT
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
